

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 2, 2023 (August 2, 2023)

**Global Medical REIT Inc.**

(Exact name of registrant as specified in its charter)

**Maryland**  
(State or Other Jurisdiction  
of Incorporation)

**001-37815**  
(Commission  
File Number)

**46-4757266**  
(I.R.S. Employer  
Identification No.)

**7373 Wisconsin Avenue, Suite 800**  
**Bethesda, MD**  
**20814**

(Address of Principal Executive Offices)  
(Zip Code)

**(202) 524-6851**  
(Registrant's Telephone Number, Including Area Code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class:</b>	<b>Trading Symbols:</b>	<b>Name of each exchange on which registered:</b>
Common Stock, par value \$0.001 per share	GMRE	NYSE
Series A Preferred Stock, par value \$0.001 per share	GMRE PrA	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On August 2, 2023, Global Medical REIT Inc. (the “Company”) announced its financial position as of June 30, 2023 and operating results for the three and six months ended June 30, 2023 and other related information (the “Earnings Release”). The Company also posted its Second Quarter 2023 Earnings Supplemental (the “Supplemental”) to the Company’s website at www.globalmedicalreit.com. The Earnings Release and Supplemental are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

The information included in this Item 2.02 of this Current Report on Form 8-K, including the Earnings Release and Supplemental, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1*</a>	<a href="#">Second Quarter 2023 Earnings Release.</a>
<a href="#">99.2*</a>	<a href="#">Second Quarter 2023 Earnings Supplemental.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

\*Furnished herewith

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Global Medical REIT Inc.**

By: /s/ Jamie A. Barber  
Jamie A. Barber  
Secretary and General Counsel

Date: August 2, 2023

---



## **Global Medical REIT Announces Second Quarter 2023 Financial Results**

### **Completes Disposition of a Four Property MOB Portfolio Receiving Gross Proceeds of \$66 million Resulting in a Gain of \$12.8 Million**

Bethesda, MD – August 2, 2023 – (BUSINESS WIRE) – Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), a net-lease medical office real estate investment trust (REIT) that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, today announced financial results for the three and six months ended June 30, 2023 and other data.

Jeffrey M. Busch, Chairman, Chief Executive Officer and President stated, “During the second quarter, we took a significant step forward in reducing our variable rate debt and leverage by selling a medical office building portfolio in Oklahoma City, Oklahoma for gross proceeds of \$66 million. We used the net proceeds from this disposition to pay down the balance of our variable rate debt, resulting in a leverage ratio as of June 30, 2023 of 44.5%. Additionally, our portfolio is producing consistent and steady results, and we ended the quarter with leased occupancy of 97%, unchanged from the first quarter. Within the current acquisition environment, we will remain disciplined as transaction markets evolve, and we are well-positioned with ample liquidity to ramp up acquisitions once spreads return to an attractive and accretive level. I would like to thank the entire team for their continued hard work and contributions to our performance.”

#### **Second Quarter 2023 Highlights**

- Net income attributable to common stockholders was \$11.8 million, or \$0.18 per diluted share, as compared to \$2.2 million, or \$0.03 per diluted share, in the comparable prior year period.
- Funds from Operations (“FFO”) of \$14.7 million, or \$0.21 per share and unit, as compared to \$16.4 million, or \$0.24 per share and unit, in the comparable prior year period.
- Adjusted Funds from Operations (“AFFO”) of \$15.9 million, or \$0.23 per share and unit, as compared to \$17.6 million, or \$0.25 per share and unit, in the comparable prior year period.
- Increased total revenue 7.9% year-over-year to \$36.4 million, primarily driven by the Company’s acquisition activity during and since the comparable prior year period and the performance of its portfolio.
- In April 2023, completed the acquisition of two medical office buildings in Redding, California, encompassing 18,698 leasable square feet, for a purchase price of \$6.7 million and a cap rate of 7.6%.
- In June 2023, sold a portfolio of four medical office buildings in Oklahoma City, Oklahoma, at a cap rate of 6.5% receiving gross proceeds of \$66 million, resulting in a gain of \$12.8 million.
- Maintained portfolio leased occupancy at 97.0% at June 30, 2023.

1



#### **Six Month and Other 2023 Highlights**

- Net income attributable to common stockholders was \$12.5 million, or \$0.19 per diluted share, as compared to \$4.9 million, or \$0.07 per diluted share, in the comparable prior year period.
- FFO of \$29.8 million, or \$0.43 per share and unit, as compared to \$32.4 million, or \$0.47 per share and unit, in the comparable prior year period.
- AFFO of \$31.8 million, or \$0.45 per share and unit, as compared to \$34.4 million, or \$0.49 per share and unit, in the comparable prior year period.
- Increased total revenue 10.7% year-over-year to \$72.6 million, primarily driven by the Company’s acquisition activity during and since the comparable prior year period and the performance of its portfolio.
- Through June 30, 2023, inclusive of the Oklahoma City disposition completed in the second quarter, completed two dispositions at a weighted average cap rate of 6.5% that generated aggregate gross proceeds of \$70.4 million, resulting in an aggregate gain of \$13.3 million.
- In August 2023, sold a medical office building located in North Charleston, South Carolina at a cap rate of 5.3%, receiving gross proceeds of \$10.1 million. This property had a net book value of approximately \$7.2 million at the time of sale.

#### **Financial Results**

Rental revenue for the second quarter 2023 increased 7.8% year-over-year to \$36.3 million, reflecting the impact of acquisitions completed during and subsequent to the second quarter of last year. Second quarter 2023 rental revenue included \$5.0 million of net lease expense recoveries, compared to \$4.4 million in the comparable prior year period.

Total expenses for the second quarter were \$35.0 million, compared to \$29.9 million for the comparable prior year period, primarily reflecting higher interest, operating, depreciation, and amortization expenses due primarily to the changes in the Company’s portfolio since the comparable prior year period as well as an increase in interest expenses due to the continued high interest rate environment.

Interest expense for the second quarter was \$8.5 million, compared to \$5.4 million for the comparable prior year period. This change reflects the impact of higher average borrowings and increased interest rates compared to the prior year period.

Net income attributable to common stockholders for the second quarter totaled \$11.8 million, or \$0.18 per diluted share, compared to \$2.2 million, or \$0.03 per diluted share, in the comparable prior year period.

The Company reported FFO of \$14.7 million, or \$0.21 per share and unit, and AFFO of \$15.9 million, or \$0.23 per share and unit, for the second quarter of 2023, compared to FFO of \$16.4 million, or \$0.24 per share and unit, and AFFO of \$17.6 million, or \$0.25 per share and unit, in the comparable prior year period.

2



### Investment Activity

During the second quarter of 2023, the Company completed the acquisition of two medical office buildings in Redding, California for an aggregate purchase price of \$6.7 million, encompassing an aggregate 18,698 leasable square feet. The Company also sold a portfolio of four medical office buildings located in Oklahoma City, Oklahoma, receiving gross proceeds of \$66.0 million, resulting in a gain of \$12.8 million.

In August 2023, the Company completed the sale of a medical office building located in North Charleston, South Carolina, at a cap rate of 5.3%, receiving gross proceeds of \$10.1 million. This property had a net book value of approximately \$7.2 million at the time of sale.

### Portfolio Update

As of June 30, 2023, the Company's portfolio was 97.0% occupied and comprised of 4.8 million leasable square feet with an annualized base rent of \$111.3 million. As of June 30, 2023, the weighted average lease term for the Company's portfolio was 5.8 years with weighted average annual rental escalations of 2.1%, and the Company's portfolio rent coverage ratio was 4.3 times.

### Balance Sheet and Capital

At June 30, 2023, total debt outstanding, including outstanding borrowings on the credit facility and notes payable (both net of unamortized debt issuance costs), was \$625.1 million and the Company's leverage was 44.5%. As of June 30, 2023, the Company's debt carried a weighted average interest rate of 4.09% and a weighted average remaining term of 3.4 years.

As of August 2, 2023, the Company's borrowing capacity under the credit facility was \$321 million.

The Company did not issue any shares of common stock under its ATM program during the second quarter of 2023 or from July 1, 2023 through August 2, 2023.

### Dividends

On June 9, 2023, the Board of Directors (the "Board") declared a \$0.21 per share cash dividend to common stockholders and unitholders of record as of June 23, 2023, which was paid on July 11, 2023, representing the Company's second quarter 2023 dividend payment. The Board also declared a \$0.46875 per share cash dividend to holders of record as of July 15, 2023 of the Company's Series A Preferred Stock, which was paid on July 31, 2023. This dividend represented the Company's quarterly dividend on its Series A Preferred Stock for the period from April 30, 2023 through July 30, 2023.

### SUPPLEMENTAL INFORMATION

Details regarding these results can be found in the Company's supplemental financial package available on the Investor Relations section of the Company's website at <http://investors.globalmedicalreit.com/>.



### CONFERENCE CALL AND WEBCAST INFORMATION

The Company will host a live webcast and conference call on Thursday, August 3, 2023 at 9:00 a.m. Eastern Time. The webcast is located on the "Investor Relations" section of the Company's website at <http://investors.globalmedicalreit.com/>.

#### To Participate via Telephone:

Dial in at least five minutes prior to start time and reference Global Medical REIT Inc.  
Domestic: 1-877-704-4453  
International: 1-201-389-0920

#### Replay:

An audio replay of the conference call will be posted on the Company's website.

### NON-GAAP FINANCIAL MEASURES

#### General

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. For the Company, non-GAAP measures consist of Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate ("EBITDAre" and "Adjusted EBITDAre"), FFO and AFFO. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate

companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented elsewhere herein.



#### *FFO and AFFO*

FFO and AFFO are non-GAAP financial measures within the meaning of the rules of the United States Securities and Exchange Commission ("SEC"). The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include: (a) recurring acquisition and disposition costs, (b) loss on the extinguishment of debt, (c) recurring straight line deferred rental revenue, (d) recurring stock-based compensation expense, (e) recurring amortization of above and below market leases, (f) recurring amortization of debt issuance costs, (g) recurring lease commissions, and (h) other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

#### *EBITDAre and Adjusted EBITDAre*

We calculate EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable.

We define Adjusted EBITDAre as EBITDAre plus non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.



#### **RENT COVERAGE RATIO**

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio ("Rent Coverage Ratio"), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 20% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) small tenant size. Additionally, included within 20% of non-reporting tenants is Pipeline Healthcare, LLC, which filed for Chapter 11 bankruptcy protection in October of 2022. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

#### **ANNUALIZED BASE RENT**

Annualized base rent represents monthly base rent for June 2023, multiplied by 12 (or base rent net of annualized expenses for properties with gross leases). Accordingly, this methodology produces an annualized amount as of a point in time but does not take into account future (i) contractual rental rate increases, (ii) leasing activity or (iii) lease expirations. Additionally, leases that are accounted for on a cash-collected basis are not included in annualized base rent.

#### **CAPITALIZATION RATE**

The capitalization rate ("cap rate") for an acquisition is calculated by dividing current Annualized Base Rent by contractual purchase price. For the portfolio capitalization rate, certain adjustments, including for subsequent capital invested, are made to the contractual purchase price.

#### **FORWARD-LOOKING STATEMENTS**

Certain statements contained herein may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company's intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements

regarding our earnings, our liquidity, our tenants' ability to pay rent to us, expected financial performance (including future cash flows associated with new tenants or the expansion of current properties), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations and future portfolio occupancy rates, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, our expected disposition activity, including the timing and/or successful completion of any dispositions and the expected use of proceeds therefrom, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company's forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

6



**Investor Relations Contact:**

Stephen Swett  
[stephen.swett@icrinc.com](mailto:stephen.swett@icrinc.com)  
 203.682.8377

7



**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Balance Sheets**  
*(unaudited, and in thousands, except par values)*

	<b>As of</b>	
	<b>June 30, 2023</b>	<b>December 31, 2022</b>
<b>Assets</b>		
Investment in real estate:		
Land	\$ 165,242	\$ 168,308
Building	1,038,464	1,079,781
Site improvements	21,404	22,024
Tenant improvements	66,544	65,987
Acquired lease intangible assets	139,715	148,077
	<u>1,431,369</u>	<u>1,484,177</u>
Less: accumulated depreciation and amortization	(218,109)	(198,218)
Investment in real estate, net	1,213,260	1,285,959
Cash and cash equivalents	2,460	4,016
Restricted cash	7,325	10,439
Tenant receivables, net	7,381	8,040
Due from related parties	391	200
Escrow deposits	9,725	7,833
Deferred assets	26,189	29,616
Derivative asset	35,864	34,705
Goodwill	5,903	5,903
Other assets	12,302	6,550
Total assets	<u>\$ 1,320,800</u>	<u>\$ 1,393,261</u>
<b>Liabilities and Equity</b>		
<b>Liabilities:</b>		
Credit Facility, net of unamortized debt issuance costs of \$8,155 and \$9,253 at June 30, 2023 and December 31, 2022, respectively	\$ 567,988	\$ 636,447
Notes payable, net of unamortized debt issuance costs of \$375 and \$452 at June 30, 2023 and December 31, 2022, respectively	57,121	57,672
Accounts payable and accrued expenses	15,457	13,819
Dividends payable	16,048	15,821
Security deposits	4,213	5,461
Other liabilities	12,137	7,363
Acquired lease intangible liability, net	6,444	7,613
Total liabilities	<u>679,408</u>	<u>744,196</u>
<b>Commitments and Contingencies</b>		
<b>Equity:</b>		
Preferred stock, \$0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at June 30, 2023 and December 31, 2022, respectively (liquidation preference of \$77,625 at June 30, 2023 and December 31, 2022, respectively)	74,959	74,959

Common stock, \$0.001 par value, 500,000 shares authorized; 65,565 shares and 65,518 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	66	66
Additional paid-in capital	722,418	721,991
Accumulated deficit	(213,744)	(198,706)
Accumulated other comprehensive income	35,859	34,674
Total Global Medical REIT Inc. stockholders' equity	619,558	632,984
Noncontrolling interest	21,834	16,081
Total equity	641,392	649,065
Total liabilities and equity	\$ 1,320,800	\$ 1,393,261

8



**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Operations**  
*(unaudited, and in thousands, except per share amounts)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
<b>Revenue</b>				
Rental revenue	\$ 36,317	\$ 33,679	\$ 72,517	\$ 65,530
Other income	34	18	64	42
Total revenue	<u>36,351</u>	<u>33,697</u>	<u>72,581</u>	<u>65,572</u>
<b>Expenses</b>				
General and administrative	4,462	4,336	8,266	8,534
Operating expenses	7,223	6,000	14,759	11,372
Depreciation expense	10,468	9,898	20,962	19,300
Amortization expense	4,337	4,138	8,732	7,915
Interest expense	8,468	5,401	16,739	10,202
Preacquisition expense	2	90	44	130
Total expenses	<u>34,960</u>	<u>29,863</u>	<u>69,502</u>	<u>57,453</u>
Income before gain on sale of investment properties	1,391	3,834	3,079	8,119
Gain on sale of investment properties	12,786	—	13,271	—
Net income	\$ 14,177	\$ 3,834	\$ 16,350	\$ 8,119
Less: Preferred stock dividends	(1,455)	(1,455)	(2,911)	(2,911)
Less: Net income attributable to noncontrolling interest	(902)	(143)	(947)	(313)
<b>Net income attributable to common stockholders</b>	<u>\$ 11,820</u>	<u>\$ 2,236</u>	<u>\$ 12,492</u>	<u>\$ 4,895</u>
Net income attributable to common stockholders per share – basic and diluted	\$ 0.18	\$ 0.03	\$ 0.19	\$ 0.07
Weighted average shares outstanding – basic and diluted	65,544	65,507	65,534	65,405

9



**Global Medical REIT Inc.**  
**Reconciliation of Net Income to FFO and AFFO**  
*(unaudited, and in thousands, except per share and unit amounts)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
<b>Net income</b>	\$ 14,177	\$ 3,834	\$ 16,350	\$ 8,119
Less: Preferred stock dividends	(1,455)	(1,455)	(2,911)	(2,911)
Depreciation and amortization expense	14,774	14,008	29,635	27,160
Gain on sale of investment properties	(12,786)	—	(13,271)	—
<b>FFO</b>	<u>\$ 14,710</u>	<u>\$ 16,387</u>	<u>\$ 29,803</u>	<u>\$ 32,368</u>
Amortization of above market leases, net	287	315	578	514
Straight line deferred rental revenue	(879)	(1,032)	(1,642)	(2,227)
Stock-based compensation expense	1,147	1,289	1,835	2,576
Amortization of debt issuance costs and other	601	514	1,202	1,029

Preacquisition expense	2	90	44	130
<b>AFFO</b>	<b>\$ 15,868</b>	<b>\$ 17,563</b>	<b>\$ 31,820</b>	<b>\$ 34,390</b>
<b>Net income attributable to common stockholders per share – basic and diluted</b>	<b>\$ 0.18</b>	<b>\$ 0.03</b>	<b>\$ 0.19</b>	<b>\$ 0.07</b>
<b>FFO per share and unit</b>	<b>\$ 0.21</b>	<b>\$ 0.24</b>	<b>\$ 0.43</b>	<b>\$ 0.47</b>
<b>AFFO per share and unit</b>	<b>\$ 0.23</b>	<b>\$ 0.25</b>	<b>\$ 0.45</b>	<b>\$ 0.49</b>
Weighted Average Shares and Units Outstanding – basic and diluted	70,434	69,698	70,119	69,485
<b>Weighted Average Shares and Units Outstanding:</b>				
Weighted Average Common Shares	65,544	65,507	65,534	65,405
Weighted Average OP Units	2,134	1,668	1,907	1,670
Weighted Average LTIP Units	2,747	2,523	2,678	2,410
Weighted Average Shares and Units Outstanding – basic and diluted	<u>70,434</u>	<u>69,698</u>	<u>70,119</u>	<u>69,485</u>

10



**Global Medical REIT Inc.**  
**Reconciliation of Net Income to EBITDAre and Adjusted EBITDAre**  
*(unaudited, and in thousands)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2023	2023	2022
<b>Net income</b>	<b>\$ 14,177</b>	<b>\$ 3,834</b>	<b>\$ 16,350</b>	<b>\$ 8,119</b>
Interest expense	8,468	5,401	16,739	10,202
Depreciation and amortization expense	14,805	14,036	29,694	27,215
Gain on sale of investment properties	(12,786)	—	(13,271)	—
<b>EBITDAre</b>	<b>\$ 24,664</b>	<b>\$ 23,271</b>	<b>\$ 49,512</b>	<b>\$ 45,536</b>
Stock-based compensation expense	1,147	1,289	1,835	2,576
Amortization of above market leases, net	287	315	578	514
Preacquisition expense	2	90	44	130
<b>Adjusted EBITDAre</b>	<b>\$ 26,100</b>	<b>\$ 24,965</b>	<b>\$ 51,969</b>	<b>\$ 48,756</b>

11



**GLOBAL  
MEDICAL REIT**



Atrium Health - Winston-Salem, NC



# **SECOND QUARTER 2023 EARNINGS SUPPLEMENTAL**

[www.globalmedicalreit.com](http://www.globalmedicalreit.com)  
NYSE: GMRE



# TABLE OF CONTENTS



Company Overview	3
Select Quarterly Financial Data	6
Business Summary	7
Portfolio Summary	8
Key Tenants/Portfolio Lease Expiration Schedule	11
Debt and Hedging Summary	12
Total Capitalization and Equity Summary	14
ESG Summary	15
Condensed Consolidated Statements of Operations	16
Condensed Consolidated Balance Sheets	17
Condensed Consolidated Statements of Cash Flows	18
Non-GAAP Reconciliations	19
Reporting Definitions and Other Disclosures	20

Legent Hospital for Special Surgery - Plano, TX


## Forward-Looking Statements

Certain statements contained herein may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company's intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding our earnings, our liquidity, our tenants' ability to pay rent to us, expected financial performance (including future cash flows associated with new tenants or the expansion of current properties), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations and future portfolio occupancy rates, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, our expected disposition activity, including the timing and/or successful completion of any dispositions and the expected use of proceeds therefrom, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company's forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

# COMPANY OVERVIEW



GLOBAL MEDICAL REIT INC. (GMRE) IS A NET-LEASE MEDICAL OFFICE REAL ESTATE INVESTMENT TRUST (REIT) THAT OWNS AND ACQUIRES HEALTHCARE FACILITIES AND LEASES THOSE FACILITIES TO PHYSICIAN GROUPS AND REGIONAL AND NATIONAL HEALTHCARE SYSTEMS.



<b>PORTFOLIO SNAPSHOT</b> (as of June 30, 2023)	
Gross Investment in Real Estate (in billions):	\$1.4
Number of Buildings:	186
Number of States:	35
Weighted Average Portfolio Cap Rate:	7.9%
% of Health System or Other Affiliated Tenants:	89%
Weighted Average Lease Term (in years):	5.8
Leased Occupancy:	97%
Portfolio Rent Coverage:	4.3x

# COMPANY OVERVIEW



## Executive Officers

Jeffrey Busch	Chairman, Chief Executive Officer and President
Robert Kiernan	Chief Financial Officer and Treasurer
Alfonzo Leon	Chief Investment Officer
Danica Holley	Chief Operating Officer
Jamie Barber	General Counsel and Corporate Secretary

## Board of Directors

Jeffrey Busch	Chairman, Chief Executive Officer and President
Henry Cole	Lead Independent Director, Compensation Committee Chair, Audit Committee Member
Paula Crowley	Audit Committee Member, ESG Committee Member, Compensation Committee Member
Matthew Cypher, Ph.D.	ESG Committee Chair, Nominating and Corporate Governance Committee Member
Ronald Marston	Nominating and Corporate Governance Committee Chair, Compensation Committee Member
Lori Wittman	Audit Committee Chair, Nominating and Corporate Governance Committee Member, ESG Committee Member
Zhang Huiqi	Director

**71%**  
INDEPENDENT DIRECTORS

**BOARD % OF WOMEN  
AND HISTORICALLY  
UNDERREPRESENTED MINORITIES**  
**43%**

# COMPANY OVERVIEW



## Corporate Headquarters

Global Medical REIT Inc.  
7373 Wisconsin Avenue, Suite 800  
Bethesda, MD 20814  
Phone: 202.524.6851  
[www.globalmedicalreit.com](http://www.globalmedicalreit.com)

## Stock Exchange

New York Stock Exchange  
Ticker: GMRE

## Investor Relations

Stephen Swett  
Phone: 203.682.8377  
Email: [stephen.swett@icrinc.com](mailto:stephen.swett@icrinc.com)

## Independent Registered Public Accounting Firm

Deloitte & Touche LLP  
McLean, VA

## Corporate and REIT Tax Counsel

Vinson & Elkins LLP  
Daniel LeBey, Corporate Partner  
Christopher Mangin, REIT Tax Partner

## Transfer Agent

American Stock Transfer & Trust Company  
Phone: 800.937.5449

## Sell-Side Analyst Coverage

<i>Firm</i>	<i>Name</i>
Baird	Wes Golladay
BMO	Juan Sanabria
B. Riley Securities	Bryan Maher
Colliers Securities	Barry Oxford
Compass Point	Merrill Ross
JMP Securities	Aaron Hecht
Janney	Robert Stevenson
KeyBanc	Austin Wurschmidt
Stifel	Stephen Manaker



# SELECT QUARTERLY FINANCIAL DATA

(unaudited, and in thousands, except per share and unit amounts)



As of Period End (Unless Otherwise Specified)	June 30,	March 31,	December 31,	September 30,	June 30,
	2023	2023	2022	2022	2022
Market capitalization (common and OP)	\$619,096	\$612,165	\$636,914	\$572,416	\$754,488
Market price per share – common	\$9.13	\$9.11	\$9.48	\$8.52	\$11.23
Common shares and OP units outstanding	67,809	67,197	67,185	67,185	67,185
Preferred equity	\$74,959	\$74,959	\$74,959	\$74,959	\$74,959
Common equity	\$544,599	\$537,795	\$558,025	\$573,707	\$559,053
Noncontrolling interest	\$21,834	\$15,721	\$16,081	\$15,918	\$15,097
Total equity	\$641,392	\$628,475	\$649,065	\$664,584	\$649,109
Investment in real estate, gross:	\$1,431,369	\$1,481,273	\$1,484,177	\$1,482,492	\$1,444,565
Borrowings:					
Credit Facility - Revolver, gross	\$76,143	\$143,500	\$145,700	\$144,700	\$260,100
Credit Facility - Term Loan A, gross	\$350,000	\$350,000	\$350,000	\$350,000	\$350,000
Credit Facility - Term Loan B, gross	\$150,000	\$150,000	\$150,000	\$150,000	-
Notes payable, gross	\$57,496	\$57,780	\$58,124	\$58,409	\$57,217
Weighted average interest rate for quarter	4.09%	4.27%	4.07%	3.65%	2.97%
Debt covenants:					
Leverage ratio (as defined in Credit Facility)	44.5%	47.4%	47.6%	47.6%	46.2%
Fixed charge coverage ratio for quarter (1.50x minimum)	2.80	2.88	3.15	3.41	3.59

Three Months Ended	June 30,	March 31,	December 31,	September 30,	June 30,
	2023	2023	2022	2022	2022
Rental revenue	\$36,317	\$36,199	\$36,290	\$35,347	\$33,679
Interest expense	\$8,468	\$8,271	\$8,064	\$6,963	\$5,401
G&A expenses	\$4,462	\$3,804	\$4,051	\$3,961	\$4,336
Depreciation and amortization expenses	\$14,805	\$14,889	\$15,093	\$14,415	\$14,036
Operating expenses	\$7,223	\$7,536	\$7,138	\$6,679	\$6,000
Total expenses	\$34,960	\$34,542	\$34,458	\$32,130	\$29,863
Gain on sale of investment properties	\$12,786	\$485	-	\$6,753	-
Net income attributable to common stockholders	\$11,820	\$673	\$369	\$8,057	\$2,236
Net income per share	\$0.18	\$0.01	\$0.01	\$0.12	\$0.03
Wtd. Avg. basic and diluted common shares (GAAP)	65,544	65,525	65,518	65,518	65,507
FFO*	\$14,710	\$15,094	\$15,457	\$16,208	\$16,387
FFO per share and unit*	\$0.21	\$0.22	\$0.22	\$0.23	\$0.24
AFFO*	\$15,868	\$15,953	\$16,522	\$17,133	\$17,563
AFFO per share and unit*	\$0.23	\$0.23	\$0.24	\$0.25	\$0.25
Wtd. avg. common shares, OP and LTIP units	70,434	69,830	69,725	69,725	69,698

## SECOND QUARTER 2023 OPERATING SUMMARY

- Net income attributable to common stockholders was \$11.8 million, or \$0.18 per diluted share, as compared to \$2.2 million, or \$0.03 per diluted share, in the comparable prior year period.
- Funds from Operations ("FFO") of \$14.7 million, or \$0.21 per share and unit, as compared to \$16.4 million, or \$0.24 per share and unit, in the comparable prior year period.
- Adjusted Funds from Operations ("AFFO") of \$15.9 million, or \$0.23 per share and unit, as compared to \$17.6 million, or \$0.25 per share and unit, in the comparable prior year period.
- Increased total revenue 7.9% year-over-year to \$36.4 million, primarily driven by the Company's acquisition activity during and since the comparable prior year period and its portfolio performance.

## COMMON AND PREFERRED DIVIDENDS

- On June 9, 2023, the Board of Directors (the "Board") declared a:
  - \$0.21 per share cash dividend to common stockholders and unitholders of record as of June 23, 2023, which was paid on July 11, 2023; and
  - \$0.46875 per share cash dividend to holders of record as of July 15, 2023, of the Company's Series A Preferred Stock, which was paid on July 31, 2023.

## INVESTMENT ACTIVITY

- In April 2023, acquired two medical office buildings (MOBs) in Redding, California, for an aggregate purchase price of \$6.7 million, encompassing an aggregate 18,698 leasable square feet.
- In June 2023, sold a portfolio of four MOBs in Oklahoma City, Oklahoma, receiving gross proceeds of \$66 million, resulting in a gain of \$12.8 million.
- In August 2023, sold a MOB in North Charleston, South Carolina, receiving gross proceeds of \$10.1 million. This property had a net book value of approximately \$7.2 million at the time of sale.

## CAPITAL MARKETS AND DEBT ACTIVITY

- Leverage was 44.5% as of June 30, 2023.
- As of August 2, 2023, we had unutilized borrowing capacity under the Credit Facility of \$321 million.
- We did not issue any shares of common stock under our ATM program during the second quarter of 2023 or from July 1, 2023 through August 2, 2023.

# PORTFOLIO SUMMARY

(as of June 30, 2023)



## PORTFOLIO STATISTICS

Gross Investment in Real Estate (in billions)	\$1.4
Total Buildings	186
Total Leasable Square Feet (in millions)	4.8
Total Tenants	268
Leased Occupancy	97%
Total Annualized Base Rent (ABR) (in millions)	\$111.3
Portfolio Rent Coverage*	4.3x
Weighted Average Cap Rate	7.9%
Weighted Average Lease Term (in years)	5.8
Weighted Average Rent Escalations	2.1%



## TENANT COMPOSITION

	<u>% of ABR</u>
Not-for-profit healthcare system	33%
For-profit healthcare system	29%
Other affiliated healthcare groups	27%
<b>Total</b>	<b>89%</b>

\* See page 21 for disclosures regarding the Company's rent coverage calculation

# PORTFOLIO SUMMARY

(as of June 30, 2023)




## LEASE TYPE

	<u>% of ABR</u>
Triple-net	54%
Absolute-net	38%
Modified gross	6%
Gross	2%

## RENT COVERAGE\*





<u>Asset Type</u>	<u>% of ABR</u>	<u>Ratio</u>
MOB	14%	5.3x
MOB/ASC	13%	5.0x
Inpatient Rehab (IRF)	17%	3.7x
Specialty Hospital <sup>(1)</sup>	6%	2.4x
<b>Total/Weighted Average</b>	<b>50%</b>	<b>4.3x</b>
<u>Tenants Not Included</u>		
Large/Credit Rated Tenants	30%	N/A
Not Reported	20%	N/A



\* See page 21 for disclosures regarding the Company's rent coverage calculation  
 1) Includes surgical hospitals, long-term acute care hospitals (LTACH) and behavioral hospitals.

# PORTFOLIO SUMMARY

(as of June 30, 2023)



# KEY TENANTS/PORTFOLIO LEASE EXPIRATION SCHEDULE



LifePoint Health operates 62 community hospital campuses, more than 50 rehabilitation and behavioral health hospitals and more than 200 additional sites of care, including managed acute rehabilitation units, outpatient centers and post-acute care facilities.

Asset Type	% of Portfolio ABR
IRF	6.9%



Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States, with a national footprint that includes 153 hospitals in 36 states and Puerto Rico.

IRF	6.6%
-----	------



MHS is the largest health system in the Parkersburg-Marietta-Vienna MSA and delivers healthcare services in southeast Ohio. MHS operates the 199-bed Marietta Memorial Hospital and two critical access hospitals, nine outpatient care centers, 26 medical staff offices, and clinical care delivery locations.

MOB	4.9%
-----	------



Based in Charlotte, North Carolina, and formed from the combination of Advocate Aurora Health and Atrium Health, Advocate serves nearly 6 million patients annually and is the fifth-largest nonprofit integrated health system in the nation. With revenues of more than \$27 billion, the newly combined organization comprises more than 1,000 sites of care and 67 hospitals.

MOB	3.7%
-----	------



Trinity Health is one of the largest not-for-profit, Catholic health care systems in the nation, with 88 hospitals, 135 continuing care locations, the second largest PACE program in the country, 136 urgent care locations and many other health and well-being services.

MOB	3.2%
-----	------

Lease Expiration Schedule (ABR in thousands)					
Year	# of Leases	Leasable	% of Total Leasable	ABR	% of Total
		Square Feet	Square Feet		ABR
2023	42	180,849	3.8%	\$3,946	3.5%
2024	68	692,348	14.5%	\$15,552	14.0%
2025	45	376,766	7.9%	\$8,876	8.0%
2026	62	511,801	10.7%	\$11,205	10.1%
2027	42	460,433	9.6%	\$12,038	10.8%
2028	27	285,707	6.0%	\$6,284	5.6%
2029	23	471,454	9.9%	\$11,459	10.3%
2030	28	398,927	8.4%	\$9,781	8.8%
2031	14	305,889	6.4%	\$6,843	6.1%
2032	7	80,310	1.7%	\$2,511	2.3%
Thereafter	42	865,425	18.1%	\$22,828	20.5%
<b>Total Leased SF</b>	<b>400</b>	<b>4,629,909</b>	<b>97.0%</b>	<b>\$111,323</b>	<b>100.0%</b>
<b>Current Vacancy</b>		<b>143,560</b>	<b>3.0%</b>		
<b>Total Leasable SF</b>		<b>4,773,469</b>	<b>100.0%</b>		


# DEBT AND HEDGING SUMMARY



## Debt Statistics As of June 30, 2023

Total Gross Debt (in thousands):	\$633,639
Fixed Rate Debt-to-Total Debt:	88%
Weighted Average Interest Rate	4.09%
Weighted Average Maturity (in years):	3.4
Leverage Ratio	44.5%
Fixed Charge Coverage Ratio	2.8

FIXED AND FLOATING RATE DEBT %



## Debt Detail (as of June 30, 2023)

Debt	Balance (in thousands)	Rate Type	Interest Rate	Maturity
<b>Unsecured Credit Facility:</b>				
Revolver:	\$76,143	Floating	SOFR + 1.50% <sup>(1)</sup>	8/1/2026 <sup>(1)</sup>
Term Loan A:	\$350,000	Fixed	3.39% <sup>(2)</sup>	May-26
Term Loan B:	\$150,000	Fixed	4.15% <sup>(2)</sup>	February-28
<b>Other:</b>				
Cantor Loan:	\$31,133	Fixed	5.22%	April-26
Rosedale Loan:	\$13,760	Fixed	3.85%	July-25
Dumfries Loan:	\$11,186	Fixed	4.68%	June-24
Toledo Loan:	\$1,417	Fixed	5.00%	July-33
<b>Total/Weighted Average:</b>	<b>\$633,639</b>		<b>4.09%</b>	<b>3.4 years</b>

(1) Credit spread of 1.50% is based on the Company's overall leverage ratio (as defined in the credit facility agreement) being between 45% and 50% during the second quarter of 2023. Pursuant to the credit facility agreement, at each reporting date the credit spread will increase or decrease based on the Company's overall leverage ratio. In addition to the credit spread we also pay 10 bps related to the transition from LIBOR to secured overnight financing rate (SOFR). The Revolver has two Company-controlled, six-month extension options. If the Company exercises those options, the maturity date of the Revolver would be August 2027.

(2) Rates reflect the effect of the Company's interest rate swaps. See table on next page for a detailed descriptions of the Company's interest rate swaps. Consists of the fixed base rate plus a credit spread of 1.45% based on a leverage ratio of between 45% and 50% under our credit facility agreement, plus 10 bps related to the transition from LIBOR to SOFR and is calculated using 365/360 method.

# DEBT AND HEDGING SUMMARY



Interest Rate Swap Detail (as of June 30, 2023) <sup>(1)</sup>			
Notional (in thousands)	Term	Weighted Average Interest Rates	
Term Loan A - \$350,000	Current – 8/2023	Fixed base rate:	1.80%
		<b>Effective interest rate:</b>	<b>3.39%<sup>(2)</sup></b>
	8/2023 – 8/2024	Fixed base rate:	1.50%
		<b>Effective interest rate:</b>	<b>3.10%<sup>(2)</sup></b>
	8/2024 – 4/2026	Fixed base rate:	1.36%
		<b>Effective interest rate:</b>	<b>2.95%<sup>(2)</sup></b>
Term Loan B - \$150,000	Current – 2/2028	Fixed base rate:	2.54%
		<b>Effective interest rate:</b>	<b>4.15%<sup>(2)</sup></b>

(1) Consists of a total of ten current interest rates swaps and five forward starting interest rate swaps whereby we pay (or will pay) the fixed base rate listed in the table above and receive the one-month SOFR, which is the reference rate for the outstanding loans in our credit facility.

(2) Consists of the fixed base rate plus a credit spread of 1.45% based on a leverage ratio of between 45% and 50% under our credit facility agreement, plus 10 bps related to the transition from LIBOR to SOFR and is calculated using 365/360 method.

# TOTAL CAPITALIZATION AND EQUITY SUMMARY



(unaudited, and in thousands, except per share data)

Total Capitalization	As of June 30, 2023
<b>Total Debt</b>	\$633,639
<b>Preferred Stock</b>	\$74,959
<b>Common Stock<sup>(1)</sup></b>	\$598,608
<b>OP Units (2,244 units)<sup>(1)</sup></b>	\$20,488
<b>Vested LTIP Units (2,151 units)<sup>(2)</sup></b>	\$—
<b>Total Capitalization</b>	<b>\$1,327,694</b>



(1) Based on the closing price of the Company's common stock on June 30, 2023, of \$9.13 per share.

(2) LTIPs are issued as equity compensation to the Company's directors and employees and, as such, have no capital value associated to them.

Equity Detail (as of June 30, 2023)				
Stock	Shares	Dividend Rate/Yield	Liquidation Preference	Optional Redemption Period
Series A Cumulative Preferred Stock, \$0.001 par value per share	3,105	7.50%	\$25 per share	Began on 9/15/2022
Common Stock, \$0.001 par value per share	65,565	9.20% <sup>(1)</sup>	N/A	N/A

(1) Calculated by dividing the aggregate dividends received for the trailing four quarters by the Company's closing stock price on June 30, 2023 of \$9.13 per share.

Preferred Dividends		
Record Date	Payment Date	Dividend (per share)
10/15/2022	10/31/2022	\$0.46875
1/15/2023	1/31/2023	\$0.46875
4/15/2023	5/1/2023	\$0.46875
7/15/2023	7/31/2023	\$0.46875
<b>Total:</b>		<b>\$1.87500</b>

Common Dividends		
Record Date	Payment Date	Dividend (per share)
9/23/2022	10/11/2022	\$0.21
12/22/2022	1/9/2023	\$0.21
3/24/2023	4/11/2023	\$0.21
6/24/2023	7/11/2023	\$0.21
<b>Total:</b>		<b>\$0.84</b>

## ENVIRONMENTAL

- We continue our efforts to quantify the energy consumption of our portfolio. For the 2022 GRESB assessment report we received a score of 46 which was higher than our 2021 score.
- We utilize the ENERGY STAR platform to collect and track our energy consumption data and have identified properties that are strong candidates for the ENERGY STAR certificate program. In 2022, we earned an ENERGY STAR certification for our Select Medical facility in Omaha, Nebraska, which scored 99, and for our Brown Clinic facility in Watertown, South Dakota, which attained a score of 84.
- We continue to build on our work with the Georgetown University's Steers Center for Global Real Estate, which established a quality assurance process and uniform collection and reporting standard for energy use.
- We incorporate climate risks and environmental sustainability assessments in our due diligence process. This has yielded actionable energy consumption mitigation recommendations and immediate access to utility consumption information. Collecting this information as part of our asset evaluation supports our ESG approach of Alignment.
- In the second quarter we published our 2022 corporate sustainability report, which can be found at <https://www.globalmedicalreit.com/about/corporate-responsibility/>.

## SOCIAL

- Our Board continues to lead our social and governance efforts. With its diverse composition, our Board is a strong example of inclusive leadership with a composition of 43% women and individuals from underrepresented groups.
- Our Board has been recognized by "Women on Boards" and our executive team reflects our demographically diverse staff.
- Our Phoenix, Arizona metro area pilot project with Ride United continued with great success. We provided 1,070 healthcare related rides to individuals in need. 60% of the rides were to medical, dental and eye appointments; 15% were to pharmacy appointments; 12% to substance use support; and 10% to mental health support. We will continue to support this program in Phoenix and expect to expand to support a similar program in Orlando, Florida.
- Our commitment to employee engagement remains a high-priority, as we continue to make accommodations for health, safety, and work-life balance. With this commitment in mind, and with the compensation committee of the Board's leadership, we conducted an employee survey that covered a comprehensive range of subjects related to our employees' attitudes about our work culture, compensation components, as well as demographic and identification data.

## GOVERNANCE

- The Board formed a standing ESG committee that oversees the Company's environmental, social, governance and resilience efforts.
- GMRE is a member of the National Association of Corporate Directors.

# CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS



(unaudited, and in thousands, except per share amounts)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2023	2022	2023	2022
<b>Revenue</b>				
Rental revenue	\$36,317	\$33,679	\$72,517	\$65,530
Other income	34	18	64	42
<b>Total revenue</b>	<b>36,351</b>	<b>33,697</b>	<b>72,581</b>	<b>65,572</b>
<b>Expenses</b>				
General and administrative	4,462	4,336	8,266	8,534
Operating expenses	7,223	6,000	14,759	11,372
Depreciation expense	10,468	9,898	20,962	19,300
Amortization expense	4,337	4,138	8,732	7,915
Interest expense	8,468	5,401	16,739	10,202
Preacquisition expense	2	90	44	130
<b>Total expenses</b>	<b>34,960</b>	<b>29,863</b>	<b>69,502</b>	<b>57,453</b>
Income before gain on sale of investment properties	1,391	3,834	3,079	8,119
Gain on sale of investment properties	12,786	—	13,271	—
<b>Net income</b>	<b>\$14,177</b>	<b>\$3,834</b>	<b>\$16,350</b>	<b>\$8,119</b>
Less: Preferred stock dividends	(1,455)	(1,455)	(2,911)	(2,911)
Less: Net income attributable to noncontrolling interest	(902)	(143)	(947)	(313)
<b>Net income attributable to common stockholders</b>	<b>\$11,820</b>	<b>\$2,236</b>	<b>\$12,492</b>	<b>\$4,895</b>
Net income attributable to common stockholders per share - basic and diluted	\$0.18	\$0.03	\$0.19	\$0.07
Weighted average shares outstanding – basic and diluted	65,544	65,507	65,534	65,405

# CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, and in thousands)



	As of	
	June 30, 2023	December 31, 2022
<b>Assets</b>		
Investment in real estate:		
Land	\$165,242	\$168,308
Building	1,038,464	1,079,781
Site improvements	21,404	22,024
Tenant improvements	66,544	65,987
Acquired lease intangible assets	139,715	148,077
	<u>1,431,369</u>	<u>1,484,177</u>
Less: accumulated depreciation and amortization	(218,109)	(198,218)
Investment in real estate, net	1,213,260	1,285,959
Cash and cash equivalents	2,460	4,016
Restricted cash	7,325	10,439
Tenant receivables, net	7,381	8,040
Due from related parties	391	200
Escrow deposits	9,725	7,833
Deferred assets	26,189	29,616
Derivative asset	35,864	34,705
Goodwill	5,903	5,903
Other assets	12,302	6,550
Total assets	<u>\$1,320,800</u>	<u>\$1,393,261</u>
<b>Liabilities and Equity</b>		
Liabilities:		
Credit Facility, net	\$567,988	\$636,447
Notes payable, net	57,121	57,672
Accounts payable and accrued expenses	15,457	13,819
Dividends payable	16,048	15,821
Security deposits	4,213	5,461
Other liabilities	12,137	7,363
Acquired lease intangible liability, net	6,444	7,613
Total liabilities	<u>679,408</u>	<u>744,196</u>
Equity:		
Preferred stock (\$77,625 liquidation preference)	74,959	74,959
Common stock	66	66
Additional paid-in capital	722,418	721,991
Accumulated deficit	(213,744)	(198,706)
Accumulated other comprehensive income	35,859	34,674
Total Global Medical REIT Inc. stockholders' equity	619,558	632,984
Noncontrolling interest	21,834	16,081
Total equity	<u>641,392</u>	<u>649,065</u>
Total liabilities and equity	<u>\$1,320,800</u>	<u>\$1,393,261</u>

# CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



(unaudited, and in thousands)

	Six Months Ended	
	June 30,	
	2023	2022
<b>Operating activities</b>		
Net income	\$16,350	\$8,119
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation expense	20,962	19,300
Amortization of acquired lease intangible assets	8,679	7,871
Amortization of above market leases, net	578	514
Amortization of debt issuance costs and other	1,202	1,029
Stock-based compensation expense	1,835	2,576
Capitalized preacquisition and other costs charged to expense	76	190
Gain on sale of investment properties	(13,271)	—
Other	121	45
Changes in operating assets and liabilities:		
Tenant receivables	659	(119)
Deferred assets	(1,731)	(2,314)
Other assets and liabilities	(224)	323
Accounts payable and accrued expenses	(339)	1,621
Security deposits	(1,248)	764
Net cash provided by operating activities	<u>33,649</u>	<u>39,919</u>
<b>Investing activities</b>		
Purchase of land, buildings, and other tangible and intangible assets and liabilities	(442)	(99,917)
Net proceeds from sale of investment properties	68,403	—
Escrow deposits for purchase of properties	—	(794)
Advances made to related parties	(191)	(174)
Capital expenditures on existing real estate investments	(2,333)	(1,509)
Leasing Commissions	(371)	—
Net cash provided by (used in) investing activities	<u>65,066</u>	<u>(102,394)</u>
<b>Financing activities</b>		
Net proceeds received from common equity offerings	—	9,979
Escrow deposits required by third party lenders	(902)	(957)
Repayment of notes payable	(628)	(552)
Proceeds from Credit Facility	24,600	92,500
Repayment of Credit Facility	(94,157)	(5,000)
Payment of debt issuance costs	—	(7)
Dividends paid to common stockholders, and OP Unit and LTIP Unit holders	(29,387)	(29,136)
Dividends paid to preferred stockholders	(2,911)	(2,911)
Net cash (used in) provided by financing activities	<u>(103,385)</u>	<u>63,916</u>
Net (decrease) increase in cash and cash equivalents and restricted cash	(4,670)	1,441
Cash and cash equivalents and restricted cash—beginning of period	14,455	12,759
Cash and cash equivalents and restricted cash—end of period	<u>\$9,785</u>	<u>\$14,200</u>

# NON-GAAP RECONCILIATIONS

(unaudited, and in thousands, except per share and unit amounts)



FFO and AFFO	Three Months Ended				
	JUN 30,	MAR 31,	DEC 31,	SEP 30,	JUN 30,
	2023	2023	2022	2022	2022
<b>Net income</b>	<b>\$14,177</b>	<b>\$2,173</b>	<b>\$1,848</b>	<b>\$10,029</b>	<b>\$3,834</b>
Less: Preferred stock dividends	(1,455)	(1,455)	(1,455)	(1,455)	(1,455)
Depreciation and amortization expense	14,774	14,861	15,064	14,387	14,008
Gain on sale of investment property	(12,786)	(485)	-	(6,753)	-
<b>FFO</b>	<b>\$14,710</b>	<b>\$15,094</b>	<b>\$15,457</b>	<b>\$16,208</b>	<b>\$16,387</b>
Amortization of above market leases, net	287	291	292	221	315
Straight line deferred rental revenue	(879)	(763)	(1,006)	(1,018)	(1,032)
Stock-based compensation expense	1,147	688	1,066	1,039	1,289
Amortization of debt issuance costs and other	601	601	601	571	514
Preacquisition expense	2	42	112	112	90
<b>AFFO</b>	<b>\$15,868</b>	<b>\$15,953</b>	<b>\$16,522</b>	<b>\$17,133</b>	<b>\$17,563</b>
<b>Net income attributable to common stockholders per share – basic and diluted</b>	<b>\$0.18</b>	<b>\$0.01</b>	<b>\$0.01</b>	<b>\$0.12</b>	<b>\$0.03</b>
<b>FFO per share and unit</b>	<b>\$0.21</b>	<b>\$0.22</b>	<b>\$0.22</b>	<b>\$0.23</b>	<b>\$0.24</b>
<b>AFFO per share and unit</b>	<b>\$0.23</b>	<b>\$0.23</b>	<b>\$0.24</b>	<b>\$0.25</b>	<b>\$0.25</b>
<b>Wtd Average Common Shares, OP and LTIP Units outstanding:</b>					
Common shares	65,544	65,525	65,518	65,518	65,507
OP units	2,134	1,667	1,668	1,668	1,668
LTIP units	2,747	2,638	2,539	2,539	2,523
<b>Wtd Average Common Shares, OP and LTIP Units Outstanding - basic and diluted</b>	<b>70,434</b>	<b>69,830</b>	<b>69,725</b>	<b>69,725</b>	<b>69,698</b>

EBITDAre and Adjusted EBITDAre	Three Months Ended				
	JUN 30,	MAR 31,	DEC 31,	SEP 30,	JUN 30,
	2023	2023	2022	2022	2022
<b>Net income</b>	<b>\$14,177</b>	<b>\$2,173</b>	<b>\$1,848</b>	<b>\$10,029</b>	<b>\$3,834</b>
Interest expense	8,468	8,271	8,064	6,963	5,401
Depreciation and amortization expense	14,805	14,889	15,093	14,415	14,036
Gain on sale of investment property	(12,786)	(485)	-	(6,753)	-
<b>EBITDAre</b>	<b>\$24,664</b>	<b>\$24,848</b>	<b>\$25,005</b>	<b>\$24,654</b>	<b>\$23,271</b>
Stock-based compensation expense	1,147	688	1,066	1,039	1,289
Amortization of above market leases, net	287	291	292	221	315
Preacquisition expense	2	42	112	112	90
<b>Adjusted EBITDAre</b>	<b>\$26,100</b>	<b>\$25,869</b>	<b>\$26,475</b>	<b>\$26,026</b>	<b>\$24,965</b>

\*See page 20 and 21 for definitions of FFO, AFFO, EBITDAre and Adjusted EBITDAre

# REPORTING DEFINITIONS AND OTHER DISCLOSURES



## **Annualized Base Rent**

Annualized base rent represents monthly base rent for June 2023, multiplied by 12 (or base rent net of annualized expenses for properties with gross leases). Accordingly, this methodology produces an annualized amount as of a point in time but does not take into account future (i) contractual rental rate increases, (ii) leasing activity or (iii) lease expirations. Additionally, leases that are accounted for on a cash-collected basis are not included in annualized base rent.

## **Capitalization Rate**

The capitalization rate ("Cap Rate") for an acquisition is calculated by dividing current Annualized Base Rent by contractual purchase price. For the portfolio capitalization rate, certain adjustments, including for subsequent capital invested, are made to the contractual purchase price.

## **Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate ("EBITDAre" and "Adjusted EBITDAre")**

We calculate EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable.

We define Adjusted EBITDAre as EBITDAre plus non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

## **Funds from Operations and Adjusted Funds from Operations**

Funds from operations ("FFO") and adjusted funds from operations ("AFFO") are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, recurring lease commissions, and other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

# REPORTING DEFINITIONS AND OTHER DISCLOSURES



## Rent Coverage Ratio

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio ("Rent Coverage Ratio"), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 20% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) small tenant size. Additionally, included within 20% of non-reporting tenants is Pipeline Healthcare, LLC, which filed for Chapter 11 bankruptcy protection in October of 2022. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

## Other Disclosures

### Non-GAAP Financial Measures

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. For the Company, non-GAAP measures consist of EBITDAre, Adjusted EBITDAre, FFO and AFFO. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented elsewhere herein.

### Additional Information

The information in this document should be read in conjunction with the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other information filed with, or furnished to, the SEC. You can access the Company's reports and amendments to those reports filed or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act in the "Investor Relations" section on the Company's website ([www.globalmedicalreit.com](http://www.globalmedicalreit.com)) under "SEC Filings" as soon as reasonably practicable after they are filed with, or furnished to, the SEC. The information on or connected to the Company's website is not, and shall not be deemed to be, a part of, or incorporated into, this Earnings Supplemental. You also can review these SEC filings and other information by accessing the SEC's website at

Certain information contained in this package, including, but not limited to, information contained in our Top 10 tenant profiles is derived from publicly-available third-party sources. The Company has not independently verified this information and there can be no assurance that such information is accurate or complete.

# INVESTOR RELATIONS

**Stephen Swett**  
203.682.8377  
stephen.swett@icrinc.com

globalmedicalreit.com  
NYSE: GMRE

